Synapse - Michael Mauro

Search Within

Michael John Mauro

Results (272)

Efficacy and safety results from ascembl, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib in patients with chronic myeloid leukemia in chronic phase after ≥2 prior tyrosine kinase inhibitors: Update after 48 weeks

Meeting Abstract

Mauro, M. J.; Minami, Y.; Rea, D.; Hochhaus, A.; Lomaia, E.; Voloshin, S.; Turkina, A. G.; Kim, D. W.; Apperley, J. F.; Cortes, J. E.; more...
Blood (2021)

Fulltext@MSK | Save

Dose modification dynamics of ponatinib in patients with chronic- phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials

Meeting Abstract

Jabbour, E.; Deininger, M.; Abruzzese, E.; Apperley, J. F.; Cortes, J. E.; Chuah, C.; DeAngelo, D.; DiPersio, J. F.; Hochhaus, A.; Lipton, J. H.; more...
Blood (2021)

Fulltext@MSK | Save

Post hoc analysis of responses to ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) by baseline BCR-ABL1 level and baseline mutation status in the OPTIC trial

Meeting Abstract

Deininger, M. W.; Apperley, J. F.; Arthur, C. K.; Chuah, C.; Hochhaus, A.; De Lavallade, H.; Lipton, J. H.; Lomaia, E.; McCloskey, J. K.; Maness, L. J.; more...
Blood (2021)

Fulltext@MSK | Save

An update of safety and efficacy results from phase 1 dose-escalation and expansion study of vodobatinib, a novel oral BCR-ABL1 tyrosine kinase inhibitor (TKI), in patients with chronic myeloid leukemia (CML) and philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) failing prior TKI therapies

Meeting Abstract

Cortes, J. E.; Saikia, T.; Kim, D. W.; Alvarado, Y.; Nicolini, F. E.; Rathnam, K.; Khattry, N.; Apperley, J. F.; Deininger, M. W.; de Lavallade, H.; more...
Blood (2021)

Fulltext@MSK | Save

Trial in progress: Asciminib in monotherapy 4 CML (AIM4CML), a phase IIIb study of asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without or with T315I mutations

Meeting Abstract

Andorsky, D.; Tomassetti, S.; Deutsch, Y. E.; Broun, E. R.; Issa, G. C.; Levy, M. Y.; Deininger, M. W.; Maegawa, R.; Shrestha, A.; Mauro, M. J.
Blood (2021)

Fulltext@MSK | Save

Lifelong TKI therapy: How to manage cardiovascular and other risks

Review

Mauro, M. J.
Hematology-American Society of Hematology Education Program (2021)

Fulltext@MSK | Save

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Journal Article

Réa, D.; Mauro, M. J.; Boquimpani, C.; Minami, Y.; Lomaia, E.; Voloshin, S.; Turkina, A.; Kim, D. W.; Apperley, J. F.; Abdo, A.; more...
Blood (2021)

Fulltext@MSK | Save

Serum antibody response in patients with philadelphia-chromosome positive or negative myeloproliferative neoplasms following vaccination with SARS-CoV-2 spike protein messenger RNA (mRNA) vaccines

Research Letter

Kozak, K. E.; Ouyang, L.; Derkach, A.; Sherman, A.; McCall, S. J.; Famulare, C.; Chervin, J.; Daley, R. J.; Morjaria, S.; Mauro, M. J.; more...
Leukemia (2021)

Fulltext@MSK | Save

Using PROMIS-preference (PROPr) scores to measure changes in quality of life after tyrosine kinase inhibitor discontinuation

Meeting Abstract

Winn, A.; Atallah, E.; Lin, L.; Thompson, J.; Moore, J.; Larson, R.; Cortes, J.; Mauro, M.; Pinilla, J.; Flynn, K.
Quality of Life Research (2021)

Fulltext@MSK | Save

OPTIC primary analysis: A dose-optimization study of 3 starting doses of ponatinib (PON)

Meeting Abstract

Cortes, J. E.; Apperley, J.; Lomaia, E.; Moiraghi, B.; Sutton, M. U.; Pavlovsky, C.; Chuah, C.; Sacha, T.; Lipton, J. H.; Schiffer, C.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save